Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


Peptech Announces Director Retirements

Peptech Announces Director Retirements

Peptech Limited (ASX:PTD, AIM: PTDx) today announced as part of its merger agreement with EvoGenix that Martin Kriewaldt and Till Medinger will retire as directors of the company, effective 28 August 2007.

Mel Bridges, Chairman of Peptech thanked both directors for the services provided to the company, commenting:

"Till has been a director of the company since 1997. He has been a consistent contributor at board level, with his international industry knowledge being particularly valuable. As Peptech's alternate director on the Domantis board, Till was instrumental in Peptech's continuing participation in Domantis and the very successful realisation of that investment.

"Since joining the Peptech Board in October 2003, Martin's litigation experience has been particularly invaluable in the disputes Peptech had with Centocor and Abbott. More recently he has used his skills in guiding Peptech through its merger and acquisition activity, spending considerable time on due diligence activities. "On behalf of the entire Peptech board I sincerely thank both these directors for their commitment to Peptech," he added.

Effective from 28 August 2007, Chris Harris and Robin Beaumont, formerly directors of EvoGenix Limited, will join the Peptech Board.

About Peptech:

Peptech Limited is a biotechnology company dedicated to developing and providing antibody and peptide-based human therapeutic products for the treatment of cancer and inflammatory diseases.

The Company has tapped its unique antibody technologies and revenues generated from its pioneering anti-TNF patents to build a range of therapeutic assets to address large and clinically validated markets.

Peptech is transitioning to a mid-stage development company as several products move from pre-clinical stages into human trials, starting with the Company's lead compound, PN0621, a differentiated anti-TNF domain antibody construct.

ENDS

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Interest Rates: Wheeler Hikes OCR To 3% On Inflationary Pressures, Eyes Kiwi

Reserve Bank governor Graeme Wheeler lifted the official cash rate for the second time in as many months, saying non-tradable inflationary pressures were "becoming apparent" in an economy that’s picking up pace and he's watching the impact of a strong kiwi dollar on import prices. More>>

ALSO:

Scoop Business: Equity Crowd Funding Carries Risks, High Failure Rate

Equity crowd funding, which became legal in New Zealand this month, comes with a high risk of failure based on figures showing existing forays into social capital have a success rate of less than 50 percent, one new entrant says. More>>

ALSO:

Scoop Business: NZ Migration Rises To 11-Year High In March

The country gained a seasonally adjusted 3,800 net new migrants in March, the most since February 2003, said Statistics New Zealand. A net 400 people left for Australia in March, down from 600 in February, according to seasonally adjusted figures. More>>

ALSO:

Hugh Pavletich: New Zealand’s Bubble Economy Is Vulnerable

The recent Forbes e-edition article by Jesse Colombo assesses the New Zealand economy “ 12 Reasons Why New Zealand's Economic Bubble Will End In Disaster ”, seems to have created quite a stir, creating extensive media coverage in New Zealand. More>>

ALSO:

Thursday Market Close: Genesis Debut Sparks Energy Rally

New Zealand stock rose after shares in the partially privatised Genesis Energy soared as much as 18 percent in its debut listing on the NZX, buoying other listed energy companies in the process. Meridian Energy, MightyRiverPower, Contact Energy and TrustPower paced gains. More>>

ALSO:

Power Outages, Roads Close: Easter Storm Moving Down Country

The NZ Transport Agency says storm conditions at the start of the Easter break are making driving hazardous in Auckland and Northland and it advises people extreme care is needed on the regions’ state highways and roads... More>>

ALSO:

Get More From Scoop

 
 
Computer Power Plus
 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news